Our Development Pipeline
At Betavive, we have a clear path from discovery to the clinic. Our lead biologic drug candidate, NH1, is advancing through the final stages of preclinical development, bringing us closer to first-in-human studies.
Alongside NH1, our promising candidates NHP16 and NHP49 are progressing through preclinical studies, helping us build a strong and diverse pipeline aimed at regenerating insulin-producing beta cells.
We are focused on the next critical milestones: completing IND-enabling toxicology studies for NH1 under GLP standards, securing partnerships for GMP manufacturing of clinical-grade material, and continuing to advance our pipeline candidates toward potential clinical development.
Each step brings us closer to transforming diabetes care by addressing the disease at its root, offering hope for patients and a new paradigm for treatment.
Prof. Aaron Ciechanover, MD, DSc
Chief Scientific Officer (CSO)
Prof. Ciechanover provides Betavive with unparalleled scientific leadership and validation. He was awarded the 2004 Nobel Prize in Chemistry for the discovery of ubiquitin-mediated protein degradation, a fundamental process that controls a vast array of cellular functions. As a Distinguished Research Professor at the Technion – Israel Institute of Technology, his foundational work in cell biology provides critical insights into the mechanisms of health and disease, guiding the innovative science behind Betavive's therapeutic approach.
Dotan Zuri, M.Sc.
Chief Technology Officer (CTO)
Dotan Zuri is an experienced biotechnology leader with over 15 years of expertise in gene therapy, cell therapy, and innovative drug discovery. Before Betavive, Mr. Zuri led preclinical initiatives at Aevi Genomic Medicine, driving a lead cell therapy platform from early-stage models to clinical studies. His expertise encompasses GLP-toxicology, preclinical development in both small and large animal models, and IND preparation to support regulatory submissions. With a strong focus on translational research, he is instrumental in bridging preclinical findings with human applications to optimize novel therapies for clinical success.
Alon Palti, LL.M.
Chief Financial Officer (CFO) & COO, Board Member
Alon Palti brings 30 years of diversified business and administrative experience in the medical arena. He was one of the initial team members at Novocure (NSDQ: NVCR), playing an instrumental role during the company's foundational years. A proven entrepreneur and executive, Mr. Palti has held senior management positions in HMOs and several medical device startups, with extensive experience in fundraising, M&A, and business development. His leadership is critical to shaping Betavive's financial strategy and driving its corporate growth.
Breakthrough therapy for diabetes
Betavive is a biotechnology company on a mission to develop a disease-modifying therapy for diabetes. We are advancing a first-in-class biological therapy designed to restore insulin-producing beta cells. Our current focus is translating this groundbreaking science from the laboratory into human clinical trials, aiming to deliver a potential long-term solution for both Type 1 and Type 2 diabetes.
Hundreds of millions of people globally live with diabetes, a chronic condition requiring constant monitoring and a lifelong regimen of injections or oral medications. Current therapies manage symptoms by replacing or supplementing insulin, but they do not address the fundamental problem: the decline and loss of the body's own insulin-producing beta cells. This leaves patients facing a daily struggle and the risk of severe long-term complications.
The Challenge:
A Lifelong Burden Beyond Symptom Management
We believe the future of diabetes treatment lies in endogenous beta cell regeneration. Betavive’s therapeutic approach is designed as a short-course, disease-modifying treatment with the potential for long-term impact. Our biological therapy is engineered to directly stimulate the patient’s own pancreatic beta cells to regenerate and proliferate. By restoring these cells, the body can naturally produce and release insulin, helping keep blood sugar levels under control. This could reduce or even eliminate the need for external insulin and other diabetes medications, potentially transforming the standard of care for both Type 1 and Type 2 diabetes.
Our Solution:
A Paradigm Shift in Diabetes Care
Our Leadership
Betavive is led by a dedicated team of seasoned scientists, drug developers, and entrepreneurs with deep expertise in endocrinology, peptide therapeutics, and the rigorous process of advancing novel medicines from the lab to the clinic.
Board of Directors
Lennart Perlhagen
Board Member
Lennart Perlhagen is a seasoned international executive, entrepreneur, and investor who co-founded the highly successful oncology company Novocure (NSDQ: NVCR). His vision and leadership were instrumental in building Novocure into a global leader. Mr. Perlhagen's extensive experience also includes numerous chairman and board member positions at other innovative MedTech and biotech companies across Europe, bringing invaluable expertise in corporate governance, strategic financing, and global market development to guide Betavive's board.
Prof. Yoram Palti, MD, PhD
Board Member
Professor Emeritus of Physiology and Biophysics at the Technion – Israel Institute of Technology, Prof. Palti is a renowned inventor and entrepreneur, and the recipient of the prestigious 2022 Israel Prize for entrepreneurship and technological innovation 🇮🇱. He is the inventor of Tumor Treating Fields (TTFields) and the co-founder of Novocure (NSDQ: NVCR), the revolutionary oncology company he built from his foundational scientific discovery. His unparalleled, prize-winning experience in translating breakthrough biology into successful clinical applications provides a powerful and unique perspective to the board.
Ricardo A. Sagrera
Board Member
Ricardo Sagrera is an experienced international investor and business leader with a focus on disruptive technologies. As a representative of key investors, he has a strong track record of identifying and supporting high-growth companies. His expertise in strategic investment and financial oversight is instrumental in guiding Betavive's long-term value creation and corporate strategy.
Scientific & Strategic Advisors
Prof. Yosef Yarden, PhD
Scientific Advisor
Professor Yosef (Yossi) Yarden of the Weizmann Institute of Science is one of the world's foremost authorities on the molecular mechanisms of cancer and cell signaling. A recipient of the prestigious Israel Prize and numerous other international awards, his pioneering research on growth factor receptors—particularly EGFR and HER2—laid the scientific foundation for blockbuster cancer therapies like Herceptin® and Erbitux®. Prof. Yarden's deep understanding of cellular growth signals, receptor activation, and therapeutic resistance provides Betavive with invaluable insights into the fundamental biology driving our regenerative peptide technology
Paul Woitach
Corporate Strategy & Business Development Advisor
Lennart Perlhagen is a seasoned international executive, entrepreneur, and investor who co-founded the highly successful oncology company Novocure (NSDQ: NVCR). His vision and leadership were instrumental in building Novocure into a global leader. Mr. Perlhagen's extensive experience also includes numerous chairman and board member positions at other innovative MedTech and biotech companies across Europe, bringing invaluable expertise in corporate governance, strategic financing, and global market development to guide Betavive's board.
Dr. Scott Rudge
CMC & Manufacturing Advisor
Dr. Scott Rudge is a leading expert in biopharmaceutical manufacturing, CMC (Chemistry, Manufacturing, and Controls), and product development. As the founder of a successful pharmaceutical consulting firm, he has extensive experience guiding companies in the development of biologics and peptides from the lab to commercial-scale GMP production. His oversight ensures Betavive's manufacturing strategy meets the highest industry and regulatory standards.
Gary Elliott, PhD, PharmD
Drug Development and Regulatory Advisor
Dr. Elliott brings 33 years of extensive experience in the biotechnology and pharmaceutical industry, offering expert perspective across preclinical, manufacturing, quality, safety, and clinical drug development strategies. Holding a PhD in Medicinal Chemistry and a PharmD in Clinical Pharmacology, he has guided overall drug development for numerous companies, including senior VP roles at Corixa Corp, Salmedix Inc., and HUYABio. Dr. Elliott possesses considerable experience authoring and supervising regulatory filings from pre-IND to NDA, coupled with extensive interaction with US, Canadian, and European regulatory authorities. He also provides critical assessment of in-licensing opportunities.
Partner with Betavive
We are at a pivotal stage of development, moving decisively towards human clinical trials. Betavive is actively seeking investment and strategic partnerships to accelerate our lead candidate and revolutionize the treatment of diabetes for millions of patients worldwide.
Let’s Talk
Want to learn more about our solutions? Talk to our experts.
